AKT1 Antibody (OTI4D6) - Azide and BSA Free
Novus Biologicals | Catalog # NBP2-70135
Key Product Details
Species Reactivity
Applications
Label
Antibody Source
Format
Product Specifications
Immunogen
Reactivity Notes
Specificity
Clonality
Host
Isotype
Theoretical MW
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Scientific Data Images for AKT1 Antibody (OTI4D6) - Azide and BSA Free
Western Blot: AKT1 Antibody (OTI4D6)Azide and BSA Free [NBP2-70135]
Western Blot: AKT1 Antibody (OTI4D6) - Azide and BSA Free [NBP2-70135] - Detection of AKT1 in human MD-MB-231 cells using AKT1 antibody NBP2-01724 at a dilution of 1:2000. WB image submitted by a verified customer review.Immunocytochemistry/ Immunofluorescence: AKT1 Antibody (OTI4D6) - Azide and BSA Free [NBP2-70135]
Immunocytochemistry/Immunofluorescence: AKT1 Antibody (OTI4D6) - Azide and BSA Free [NBP2-70135] - Staining of COS7 cells transiently transfected by pCMV6-ENTRY AKT1.Immunohistochemistry: AKT1 Antibody (OTI4D6) - Azide and BSA Free [NBP2-70135]
Immunohistochemistry: AKT1 Antibody (OTI4D6) - Azide and BSA Free [NBP2-70135] - IHC-P staining of paraffin-embedded human kidney tissue using anti-AKT1 antibody. Heat-induced epitope retrieval in 10 mM citric buffer, pH 6.0, 100C for 10 min.Flow Cytometry: AKT1 Antibody (OTI4D6) - Azide and BSA Free [NBP2-70135]
Flow Cytometry: AKT1 Antibody (OTI4D6) - Azide and BSA Free [NBP2-70135] - Flow cytometric analysis of Jurkat cells using anti-AKT1 antibody (red), compared to a nonspecific negative control antibody (blue).Western Blot: AKT1 Antibody (OTI4D6)Azide and BSA Free [NBP2-70135]
Western Blot: AKT1 Antibody (OTI4D6) - Azide and BSA Free [NBP2-70135] - HEK293T cells were transfected with the pCMV6-ENTRY control (left lane) or pCMV6-ENTRY AKT1 (right lane) cDNA for 48 hrs and lysed. Equivalent amounts of cell lysates (5 ug per lane) were separated by SDS-PAGE and immunoblotted with anti-AKT1.Western Blot: AKT1 Antibody (OTI4D6)Azide and BSA Free [NBP2-70135]
Western Blot: AKT1 Antibody (OTI4D6) - Azide and BSA Free [NBP2-70135] - Analysis of extracts (10 ug) from a mouse cell line and 3 different mouse tissues using AKT1 antibody at a 1:200 dilution.Western Blot: AKT1 Antibody (OTI4D6)Azide and BSA Free [NBP2-70135]
Western Blot: AKT1 Antibody (OTI4D6) - Azide and BSA Free [NBP2-70135] - Analysis of extracts (35 ug) from 9 different cell lines using AKT1 antibody.Immunohistochemistry: AKT1 Antibody (OTI4D6) - Azide and BSA Free [NBP2-70135]
Immunohistochemistry: AKT1 Antibody (OTI4D6) - Azide and BSA Free [NBP2-70135] - IHC-P staining of paraffin-embedded adenocarcinoma of human endometrium tissue using anti-AKT1 antibody. Heat-induced epitope retrieval in10 mM citric buffer, pH 6.0, 100C for 10 min.Immunohistochemistry: AKT1 Antibody (OTI4D6) - Azide and BSA Free [NBP2-70135]
Immunohistochemistry: AKT1 Antibody (OTI4D6) - Azide and BSA Free [NBP2-70135] - IHC-P staining of paraffin-embedded carcinoma of human bladder tissue using anti-AKT1 antibody. Heat-induced epitope retrieval in 10 mM citric buffer, pH 6.0, 100C for 10 min.Immunohistochemistry: AKT1 Antibody (OTI4D6) - Azide and BSA Free [NBP2-70135]
Immunohistochemistry: AKT1 Antibody (OTI4D6) - Azide and BSA Free [NBP2-70135] - IHC-P staining of paraffin-embedded carcinoma of human kidney tissue using AKT1 antibody. Heat-induced epitope retrieval in 10 mM citric buffer, pH 6.0, 100C for 10 min.Immunohistochemistry: AKT1 Antibody (OTI4D6) - Azide and BSA Free [NBP2-70135]
Immunohistochemistry: AKT1 Antibody (OTI4D6) - Azide and BSA Free [NBP2-70135] - IHC-P staining of paraffin-embedded human prostate tissue using anti-AKT1 antibody. Heat-induced epitope retrieval in 10 mM citric buffer, pH 6.0, 100C for 10 min.Applications for AKT1 Antibody (OTI4D6) - Azide and BSA Free
Flow Cytometry
Immunocytochemistry/ Immunofluorescence
Immunohistochemistry
Immunohistochemistry-Paraffin
Western Blot
Flow Cytometry Panel Builder
Bio-Techne Knows Flow Cytometry
Save time and reduce costly mistakes by quickly finding compatible reagents using the Panel Builder Tool.
Advanced Features
- Spectra Viewer - Custom analysis of spectra from multiple fluorochromes
- Spillover Popups - Visualize the spectra of individual fluorochromes
- Antigen Density Selector - Match fluorochrome brightness with antigen density
Formulation, Preparation, and Storage
Purification
Reconstitution
Formulation
Format
Preservative
Concentration
Shipping
Stability & Storage
Calculators
Background: Akt1
The main function of AKT is to control inhibition of apoptosis and promote cell proliferation. Survival factors can activate AKT Ser473 and Thr308 phosphorylation sites in a transcription-independent manner, resulting in the inactivation of apoptotic signaling transduction through the tumor suppressor PTEN, an antagonist to PI3-K (5). PTEN exerts enzymatic activity as a phosphatidylinositol-3,4,5-trisphosphate (PIP3) phosphatase, opposing PI3K activity by decreasing availability of PIP3 to proliferating cells, leading to overexpression and inappropriate activation of AKT noted in many types of cancer.
AKT1 function has been linked to overall physiological growth and function (2). AKT1 has been correlated with proteus syndrome, a rare disorder characterized by overgrowth of various tissues caused by a mosaic variant in the AKT1 gene in humans.
AKT2 is strongly correlated with Type II diabetes, including phenotypes of insulin resistance, hyperglycemia and atherosclerosis (2, 6).
The function of AKT3 is specifically associated to brain development, where disruptions to AKT3 are correlated with microcephaly, hemimegalencephaly, megalencephaly and intellectual disabilities (2).
References
1. Ersahin, T., Tuncbag, N., & Cetin-Atalay, R. (2015). The PI3K/AKT/mTOR interactive pathway. Mol Biosyst, 11(7), 1946-1954. doi:10.1039/c5mb00101c
2. Cohen, M. M., Jr. (2013). The AKT genes and their roles in various disorders. Am J Med Genet A, 161a(12), 2931-2937. doi:10.1002/ajmg.a.36101
3. Georgescu, M. M. (2010). PTEN Tumor Suppressor Network in PI3K-Akt Pathway Control. Genes Cancer, 1(12), 1170-1177. doi:10.1177/1947601911407325
4. Mishra, P., Paital, B., Jena, S., Swain, S. S., Kumar, S., Yadav, M. K.,... Samanta, L. (2019). Possible activation of NRF2 by Vitamin E/Curcumin against altered thyroid hormone induced oxidative stress via NFkB/AKT/mTOR/KEAP1 signalling in rat heart. Sci Rep, 9(1), 7408. doi:10.1038/s41598-019-43320-5
5. Wedel, S., Hudak, L., Seibel, J. M., Juengel, E., Oppermann, E., Haferkamp, A., & Blaheta, R. A. (2011). Critical analysis of simultaneous blockage of histone deacetylase and multiple receptor tyrosine kinase in the treatment of prostate cancer. Prostate, 71(7), 722-735. doi:10.1002/pros.21288
6. Rotllan, N., Chamorro-Jorganes, A., Araldi, E., Wanschel, A. C., Aryal, B., Aranda, J. F.,... Fernandez-Hernando, C. (2015). Hematopoietic Akt2 deficiency attenuates the progression of atherosclerosis. Faseb j, 29(2), 597-610. doi:10.1096/fj.14-262097
Long Name
Alternate Names
Gene Symbol
Additional Akt1 Products
Product Documents for AKT1 Antibody (OTI4D6) - Azide and BSA Free
Certificate of Analysis
To download a Certificate of Analysis, please enter a lot or batch number in the search box below.
Product Specific Notices for AKT1 Antibody (OTI4D6) - Azide and BSA Free
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Customer Reviews for AKT1 Antibody (OTI4D6) - Azide and BSA Free
There are currently no reviews for this product. Be the first to review AKT1 Antibody (OTI4D6) - Azide and BSA Free and earn rewards!
Have you used AKT1 Antibody (OTI4D6) - Azide and BSA Free?
Submit a review and receive an Amazon gift card!
$25/€18/£15/$25CAN/¥2500 Yen for a review with an image
$10/€7/£6/$10CAN/¥1110 Yen for a review without an image
Submit a review
Protocols
Find general support by application which include: protocols, troubleshooting, illustrated assays, videos and webinars.
- 7-Amino Actinomycin D (7-AAD) Cell Viability Flow Cytometry Protocol
- Antigen Retrieval Protocol (PIER)
- Antigen Retrieval for Frozen Sections Protocol
- Appropriate Fixation of IHC/ICC Samples
- Cellular Response to Hypoxia Protocols
- Chromogenic IHC Staining of Formalin-Fixed Paraffin-Embedded (FFPE) Tissue Protocol
- Chromogenic Immunohistochemistry Staining of Frozen Tissue
- ClariTSA™ Fluorophore Kits
- Detection & Visualization of Antibody Binding
- Extracellular Membrane Flow Cytometry Protocol
- Flow Cytometry Protocol for Cell Surface Markers
- Flow Cytometry Protocol for Staining Membrane Associated Proteins
- Flow Cytometry Staining Protocols
- Flow Cytometry Troubleshooting Guide
- Fluorescent IHC Staining of Frozen Tissue Protocol
- Graphic Protocol for Heat-induced Epitope Retrieval
- Graphic Protocol for the Preparation and Fluorescent IHC Staining of Frozen Tissue Sections
- Graphic Protocol for the Preparation and Fluorescent IHC Staining of Paraffin-embedded Tissue Sections
- Graphic Protocol for the Preparation of Gelatin-coated Slides for Histological Tissue Sections
- ICC Cell Smear Protocol for Suspension Cells
- ICC Immunocytochemistry Protocol Videos
- ICC for Adherent Cells
- IHC Sample Preparation (Frozen sections vs Paraffin)
- Immunocytochemistry (ICC) Protocol
- Immunocytochemistry Troubleshooting
- Immunofluorescence of Organoids Embedded in Cultrex Basement Membrane Extract
- Immunofluorescent IHC Staining of Formalin-Fixed Paraffin-Embedded (FFPE) Tissue Protocol
- Immunohistochemistry (IHC) and Immunocytochemistry (ICC) Protocols
- Immunohistochemistry Frozen Troubleshooting
- Immunohistochemistry Paraffin Troubleshooting
- Intracellular Flow Cytometry Protocol Using Alcohol (Methanol)
- Intracellular Flow Cytometry Protocol Using Detergents
- Intracellular Nuclear Staining Flow Cytometry Protocol Using Detergents
- Intracellular Staining Flow Cytometry Protocol Using Alcohol Permeabilization
- Intracellular Staining Flow Cytometry Protocol Using Detergents to Permeabilize Cells
- Preparing Samples for IHC/ICC Experiments
- Preventing Non-Specific Staining (Non-Specific Binding)
- Primary Antibody Selection & Optimization
- Propidium Iodide Cell Viability Flow Cytometry Protocol
- Protocol for Heat-Induced Epitope Retrieval (HIER)
- Protocol for Liperfluo
- Protocol for Making a 4% Formaldehyde Solution in PBS
- Protocol for VisUCyte™ HRP Polymer Detection Reagent
- Protocol for the Characterization of Human Th22 Cells
- Protocol for the Characterization of Human Th9 Cells
- Protocol for the Fluorescent ICC Staining of Cell Smears - Graphic
- Protocol for the Fluorescent ICC Staining of Cultured Cells on Coverslips - Graphic
- Protocol for the Preparation & Fixation of Cells on Coverslips
- Protocol for the Preparation and Chromogenic IHC Staining of Frozen Tissue Sections
- Protocol for the Preparation and Chromogenic IHC Staining of Frozen Tissue Sections - Graphic
- Protocol for the Preparation and Chromogenic IHC Staining of Paraffin-embedded Tissue Sections
- Protocol for the Preparation and Chromogenic IHC Staining of Paraffin-embedded Tissue Sections - Graphic
- Protocol for the Preparation and Fluorescent ICC Staining of Cells on Coverslips
- Protocol for the Preparation and Fluorescent ICC Staining of Non-adherent Cells
- Protocol for the Preparation and Fluorescent ICC Staining of Stem Cells on Coverslips
- Protocol for the Preparation and Fluorescent IHC Staining of Frozen Tissue Sections
- Protocol for the Preparation and Fluorescent IHC Staining of Paraffin-embedded Tissue Sections
- Protocol for the Preparation of Gelatin-coated Slides for Histological Tissue Sections
- Protocol for the Preparation of a Cell Smear for Non-adherent Cell ICC - Graphic
- Protocol: Annexin V and PI Staining by Flow Cytometry
- Protocol: Annexin V and PI Staining for Apoptosis by Flow Cytometry
- R&D Systems Quality Control Western Blot Protocol
- TUNEL and Active Caspase-3 Detection by IHC/ICC Protocol
- The Importance of IHC/ICC Controls
- Troubleshooting Guide: Fluorokine Flow Cytometry Kits
- Troubleshooting Guide: Immunohistochemistry
- Troubleshooting Guide: Western Blot Figures
- Western Blot Conditions
- Western Blot Protocol
- Western Blot Protocol for Cell Lysates
- Western Blot Troubleshooting
- Western Blot Troubleshooting Guide
- View all Protocols, Troubleshooting, Illustrated assays and Webinars
FAQs for AKT1 Antibody (OTI4D6) - Azide and BSA Free
-
Q: Do your HRP-conjugated antibodies contain sodium azide?
A: No. None of our HRP-conjugated antibodies contain sodium azide as this agent inhibits the activity of HRP.
-
Q: How do I choose secondary antibodies to label the same cells when I have two primary antibodies from the same host?
A: Use isotype-specific secondary antibodies if the primary antibodies are of different isotypes. You can also make direct conjugates of the primary antibodies by use of antibody labeling kits, dyes, or custom conjugations (please contact Technical Support for custom orders).
-
Q: I am looking for a antibody that recognizes human Akt1 but NOT Akt2 or 3, for Western blot analyses. I also want that antibody to recognize Akt1 regardless of its phosphorylated form.
A: At the moment we do not have an AKT1 antibody that definitively does not react with either AKT2 or AKT3.
-
Q: What is the molecular weight of your antibodies?
A: All IgG antibodies are approximately 150 kDa (each heavy chain is about 50 kDa and each light chain is about 25 kDa).
-
Q: What is trehalose and why is it in the formulation?
A: Trehalose is an effective sugar for stabilizing proteins against damage caused by freezing. It can also make proteins more resistant to moisture when lyophilized, resulting in a product that is less likely to precipitate when reconstituted. Trehalose does not react with amino acids or proteins as part of the Maillard reaction. It is found in nature in many plants and animals.
-
Q: Why are many of your antibodies formulated with sodium azide and BSA?
A: Sodium azide is a preservative which is added to prevent bacterial growth. BSA is added as a protein stabilizer.
-
Q: Will trehalose affect the performance of the protein or antibody in my specific application?
A: Usually, there are no adverse effects in bioassays or other applications. However, we advised to run a control to determine if the concentration of trehalose in the antibody formulation has any adverse effects.
-
Q: Do your HRP-conjugated antibodies contain sodium azide?
A: No. None of our HRP-conjugated antibodies contain sodium azide as this agent inhibits the activity of HRP.
-
Q: How do I choose secondary antibodies to label the same cells when I have two primary antibodies from the same host?
A: Use isotype-specific secondary antibodies if the primary antibodies are of different isotypes. You can also make direct conjugates of the primary antibodies by use of antibody labeling kits, dyes, or custom conjugations (please contact Technical Support for custom orders).
-
Q: I am looking for a antibody that recognizes human Akt1 but NOT Akt2 or 3, for Western blot analyses. I also want that antibody to recognize Akt1 regardless of its phosphorylated form.
A: At the moment we do not have an AKT1 antibody that definitively does not react with either AKT2 or AKT3.
-
Q: What is the molecular weight of your antibodies?
A: All IgG antibodies are approximately 150 kDa (each heavy chain is about 50 kDa and each light chain is about 25 kDa).
-
Q: What is trehalose and why is it in the formulation?
A: Trehalose is an effective sugar for stabilizing proteins against damage caused by freezing. It can also make proteins more resistant to moisture when lyophilized, resulting in a product that is less likely to precipitate when reconstituted. Trehalose does not react with amino acids or proteins as part of the Maillard reaction. It is found in nature in many plants and animals.
-
Q: Why are many of your antibodies formulated with sodium azide and BSA?
A: Sodium azide is a preservative which is added to prevent bacterial growth. BSA is added as a protein stabilizer.
-
Q: Will trehalose affect the performance of the protein or antibody in my specific application?
A: Usually, there are no adverse effects in bioassays or other applications. However, we advised to run a control to determine if the concentration of trehalose in the antibody formulation has any adverse effects.
-
Q: Do your HRP-conjugated antibodies contain sodium azide?
A: No. None of our HRP-conjugated antibodies contain sodium azide as this agent inhibits the activity of HRP.
-
Q: How do I choose secondary antibodies to label the same cells when I have two primary antibodies from the same host?
A: Use isotype-specific secondary antibodies if the primary antibodies are of different isotypes. You can also make direct conjugates of the primary antibodies by use of antibody labeling kits, dyes, or custom conjugations (please contact Technical Support for custom orders).
-
Q: I am looking for a antibody that recognizes human Akt1 but NOT Akt2 or 3, for Western blot analyses. I also want that antibody to recognize Akt1 regardless of its phosphorylated form.
A: At the moment we do not have an AKT1 antibody that definitively does not react with either AKT2 or AKT3.
-
Q: What is the molecular weight of your antibodies?
A: All IgG antibodies are approximately 150 kDa (each heavy chain is about 50 kDa and each light chain is about 25 kDa).
-
Q: What is trehalose and why is it in the formulation?
A: Trehalose is an effective sugar for stabilizing proteins against damage caused by freezing. It can also make proteins more resistant to moisture when lyophilized, resulting in a product that is less likely to precipitate when reconstituted. Trehalose does not react with amino acids or proteins as part of the Maillard reaction. It is found in nature in many plants and animals.
-
Q: Why are many of your antibodies formulated with sodium azide and BSA?
A: Sodium azide is a preservative which is added to prevent bacterial growth. BSA is added as a protein stabilizer.
-
Q: Will trehalose affect the performance of the protein or antibody in my specific application?
A: Usually, there are no adverse effects in bioassays or other applications. However, we advised to run a control to determine if the concentration of trehalose in the antibody formulation has any adverse effects.
-
Q: Do your HRP-conjugated antibodies contain sodium azide?
A: No. None of our HRP-conjugated antibodies contain sodium azide as this agent inhibits the activity of HRP.
-
Q: How do I choose secondary antibodies to label the same cells when I have two primary antibodies from the same host?
A: Use isotype-specific secondary antibodies if the primary antibodies are of different isotypes. You can also make direct conjugates of the primary antibodies by use of antibody labeling kits, dyes, or custom conjugations (please contact Technical Support for custom orders).
-
Q: I am looking for a antibody that recognizes human Akt1 but NOT Akt2 or 3, for Western blot analyses. I also want that antibody to recognize Akt1 regardless of its phosphorylated form.
A: At the moment we do not have an AKT1 antibody that definitively does not react with either AKT2 or AKT3.
-
Q: What is the molecular weight of your antibodies?
A: All IgG antibodies are approximately 150 kDa (each heavy chain is about 50 kDa and each light chain is about 25 kDa).
-
Q: What is trehalose and why is it in the formulation?
A: Trehalose is an effective sugar for stabilizing proteins against damage caused by freezing. It can also make proteins more resistant to moisture when lyophilized, resulting in a product that is less likely to precipitate when reconstituted. Trehalose does not react with amino acids or proteins as part of the Maillard reaction. It is found in nature in many plants and animals.
-
Q: Why are many of your antibodies formulated with sodium azide and BSA?
A: Sodium azide is a preservative which is added to prevent bacterial growth. BSA is added as a protein stabilizer.
-
Q: Will trehalose affect the performance of the protein or antibody in my specific application?
A: Usually, there are no adverse effects in bioassays or other applications. However, we advised to run a control to determine if the concentration of trehalose in the antibody formulation has any adverse effects.
-
Q: Do your HRP-conjugated antibodies contain sodium azide?
A: No. None of our HRP-conjugated antibodies contain sodium azide as this agent inhibits the activity of HRP.
-
Q: How do I choose secondary antibodies to label the same cells when I have two primary antibodies from the same host?
A: Use isotype-specific secondary antibodies if the primary antibodies are of different isotypes. You can also make direct conjugates of the primary antibodies by use of antibody labeling kits, dyes, or custom conjugations (please contact Technical Support for custom orders).
-
Q: I am looking for a antibody that recognizes human Akt1 but NOT Akt2 or 3, for Western blot analyses. I also want that antibody to recognize Akt1 regardless of its phosphorylated form.
A: At the moment we do not have an AKT1 antibody that definitively does not react with either AKT2 or AKT3.
-
Q: What is the molecular weight of your antibodies?
A: All IgG antibodies are approximately 150 kDa (each heavy chain is about 50 kDa and each light chain is about 25 kDa).
-
Q: What is trehalose and why is it in the formulation?
A: Trehalose is an effective sugar for stabilizing proteins against damage caused by freezing. It can also make proteins more resistant to moisture when lyophilized, resulting in a product that is less likely to precipitate when reconstituted. Trehalose does not react with amino acids or proteins as part of the Maillard reaction. It is found in nature in many plants and animals.
-
Q: Why are many of your antibodies formulated with sodium azide and BSA?
A: Sodium azide is a preservative which is added to prevent bacterial growth. BSA is added as a protein stabilizer.
-
Q: Will trehalose affect the performance of the protein or antibody in my specific application?
A: Usually, there are no adverse effects in bioassays or other applications. However, we advised to run a control to determine if the concentration of trehalose in the antibody formulation has any adverse effects.
-
Q: Do your HRP-conjugated antibodies contain sodium azide?
A: No. None of our HRP-conjugated antibodies contain sodium azide as this agent inhibits the activity of HRP.
-
Q: How do I choose secondary antibodies to label the same cells when I have two primary antibodies from the same host?
A: Use isotype-specific secondary antibodies if the primary antibodies are of different isotypes. You can also make direct conjugates of the primary antibodies by use of antibody labeling kits, dyes, or custom conjugations (please contact Technical Support for custom orders).
-
Q: I am looking for a antibody that recognizes human Akt1 but NOT Akt2 or 3, for Western blot analyses. I also want that antibody to recognize Akt1 regardless of its phosphorylated form.
A: At the moment we do not have an AKT1 antibody that definitively does not react with either AKT2 or AKT3.
-
Q: What is the molecular weight of your antibodies?
A: All IgG antibodies are approximately 150 kDa (each heavy chain is about 50 kDa and each light chain is about 25 kDa).
-
Q: What is trehalose and why is it in the formulation?
A: Trehalose is an effective sugar for stabilizing proteins against damage caused by freezing. It can also make proteins more resistant to moisture when lyophilized, resulting in a product that is less likely to precipitate when reconstituted. Trehalose does not react with amino acids or proteins as part of the Maillard reaction. It is found in nature in many plants and animals.
-
Q: Why are many of your antibodies formulated with sodium azide and BSA?
A: Sodium azide is a preservative which is added to prevent bacterial growth. BSA is added as a protein stabilizer.
-
Q: Will trehalose affect the performance of the protein or antibody in my specific application?
A: Usually, there are no adverse effects in bioassays or other applications. However, we advised to run a control to determine if the concentration of trehalose in the antibody formulation has any adverse effects.
-
Q: Do your HRP-conjugated antibodies contain sodium azide?
A: No. None of our HRP-conjugated antibodies contain sodium azide as this agent inhibits the activity of HRP.
-
Q: How do I choose secondary antibodies to label the same cells when I have two primary antibodies from the same host?
A: Use isotype-specific secondary antibodies if the primary antibodies are of different isotypes. You can also make direct conjugates of the primary antibodies by use of antibody labeling kits, dyes, or custom conjugations (please contact Technical Support for custom orders).
-
Q: I am looking for a antibody that recognizes human Akt1 but NOT Akt2 or 3, for Western blot analyses. I also want that antibody to recognize Akt1 regardless of its phosphorylated form.
A: At the moment we do not have an AKT1 antibody that definitively does not react with either AKT2 or AKT3.
-
Q: What is the molecular weight of your antibodies?
A: All IgG antibodies are approximately 150 kDa (each heavy chain is about 50 kDa and each light chain is about 25 kDa).
-
Q: What is trehalose and why is it in the formulation?
A: Trehalose is an effective sugar for stabilizing proteins against damage caused by freezing. It can also make proteins more resistant to moisture when lyophilized, resulting in a product that is less likely to precipitate when reconstituted. Trehalose does not react with amino acids or proteins as part of the Maillard reaction. It is found in nature in many plants and animals.
-
Q: Why are many of your antibodies formulated with sodium azide and BSA?
A: Sodium azide is a preservative which is added to prevent bacterial growth. BSA is added as a protein stabilizer.
-
Q: Will trehalose affect the performance of the protein or antibody in my specific application?
A: Usually, there are no adverse effects in bioassays or other applications. However, we advised to run a control to determine if the concentration of trehalose in the antibody formulation has any adverse effects.